Prognostic factors in Ewing's tumor of bone:: Analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study group
Prognostic factors in Ewing's tumor of bone:: Analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study group
复制标题
DOI：
10.1200/jco.2000.18.17.3108
复制
发表时间：
2000-09-01
影响因子：
45.3
通讯作者：
Craft, AW
中科院分区：
文献类型：
--
作者：
Cotterill, SJ;Ahrens, S;Craft, AW
目的：进一步阐述骨尤文肉瘤的预后因素，并记录研究期间无复发生存期（RFS）的改善和局部治疗的趋势（1977年至1993年）。患者和方法：对联合的Gesellschaft Fur Padiatrische Onkologie und Hamatologie/Cooperative Ewing Sarcoma Study和United Kingdom Children's Cancer Study Group/医学研究理事会数据集，975例患者在当前的欧洲组间合作尤因肉瘤研究试验前在各自的试验办公室注册。两组在此期间独立进行了类似化疗的研究。结果：关键的不良预后因素是诊断时的转移（5年RFS，诊断时有转移的患者为22%，诊断时无转移的患者为55%; P
Purpose: To further elaborate on prognostic factors for Ewing's sarcoma of bone and to document improvements in relapse-free survival (RFS) and trends in local therapy over the study period (1977 to 1993).Patients and Methods: A retrospective analysis was performed on a combined Gesellschaft Fur Padiatrische Onkologie und Hamatologie/Cooperative Ewing Sarcoma Study and United Kingdom Children's Cancer Study Group/Medical Research Council data set of 975 patients registered with the respective trial offices before the current collaborative European Intergroup Cooperative Ewing's Sarcoma Study trial. Both groups independently undertook studies with similar chemotherapy during the period.Results: The key adverse prognostic factor is metastases at diagnosis (5-year RFS, 22% of patients with metastases at diagnosis v 55% of patients without metastases at diagnosis; P